We review research regarding the epidemiology, risk factors, genetic susceptibility,
molecular pathology, and early detection of SCLC, a deadly tumor that accounts for 14% of …

Automatic lung disease detection is a critical challenging task for researchers because of the
noise signals getting included into creative signals amid the image capturing process which …

Background Concurrent chemoradiotherapy is standard treatment for limited stage small-cell
lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered …

Six different acylthiourea ligands (L1–L6) and their corresponding Ru (II)-p-cymene
complexes (P1–P6) were designed to explore the structure–activity relationship of the …

Background Lung cancer is the second most common cancer and the main cause of cancer-
related mortality worldwide. In spite of various efforts that have been made to facilitate the …

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈ 15%) are
small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for …

PURPOSE: Epidemiological studies on neuroendocrine tumours (NETs) generally show a
major increase in incidence. To investigate this increase, epidemiological data from the …

Purpose Considering promising results in phase II studies, a randomized phase III trial was
designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide …

Over the past several years, long non‐coding RNAs (lncRNAs) have attracted more and
more attention due to their special functions. They are vital biomarkers in multiple diseases …

Serological cell death biomarkers and circulating tumor cells (CTCs) have potential uses as
tools for pharmacodynamic blood-based assays and their subsequent application to early …